International Journal of Molecular Sciences | |
Using a Novel MicroRNA Delivery System to Inhibit Osteoclastogenesis | |
Yanlan Yao2  Tingting Jia2  Yang Pan1  Hongna Gou2  Yulong Li2  Yu Sun2  Rui Zhang2  Kuo Zhang2  Guigao Lin2  Jiehong Xie2  Jinming Li2  Lunan Wang2  | |
[1] Institute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control (CDC), Beijing 100013, China; E-Mail:;National Center for Clinical Laboratories, Beijing Hospital, No. 1 Dahua Road, Dongdan, Beijing 100730, China; E-Mails: | |
关键词: MS2 VLP; miR-146a; rheumatoid arthritis; osteoporosis; osteoclast; | |
DOI : 10.3390/ijms16048337 | |
来源: mdpi | |
【 摘 要 】
Previously, we developed a novel microRNA (miRNA) delivery system based on bacteriophage MS2 virus-like particles (MS2 VLPs). In this current study, we used this system to transport miR-146a into human peripheral blood mononuclear cells (PBMCs), and demonstrated the inhibition of osteoclastogenesis in precursors. Two cytokines, receptor activator of NF-κB ligand (RANKL), and macrophage-colony stimulating factor (M-CSF) were used to induce osteoclastogenesis. MS2 VLPs were transfected into PBMCs. qRT-PCR was applied to measure expression levels of miR-146a and osteoclast (OC)-specific genes. Western blot (WB) was conducted to evaluate miR-146a downstream target proteins: epidermal growth factor receptor (EGFR) and tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6). The formation and activity of OCs were assessed by cytochemical staining and bone resorption assay, respectively. In PBMCs treated with MS2-miR146a VLPs, qRT-PCR assays showed increased expression of miR-146a (
【 授权许可】
CC BY
© 2015 by the authors; licensee MDPI, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190014404ZK.pdf | 3572KB | download |